Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.
You may also be interested in...
FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC
Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.
FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC
Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.
Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
Failed single-agent trial is small setback for Sutent, analyst says. Pfizer has three combination trials also ongoing in breast cancer settings.